These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17064755)

  • 1. Changes in blood viscosity with the recombinant tissue plasminogen activator alteplase.
    Hitosugi M; Omura K; Yufu T; Kido M; Niwa M; Nagai T; Tokudome S
    Thromb Res; 2007; 120(3):447-50. PubMed ID: 17064755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
    Wootton DM; Popel AS; Alevriadou BR
    Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibronectin decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator.
    Beckmann R; Geiger M; de Vries C; Pannekoek H; Binder BR
    J Biol Chem; 1991 Feb; 266(4):2227-32. PubMed ID: 1824940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
    He S; Zhu K; Skeppholm M; Vedin J; Svensson J; Egberg N; Blombäck M; Wallen H
    Thromb Haemost; 2007 Oct; 98(4):871-82. PubMed ID: 17938814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188.
    Hunter RL; Papadea C; Gallagher CJ; Finlayson DC; Check IJ
    Thromb Haemost; 1990 Feb; 63(1):6-12. PubMed ID: 2339361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen assay by means of the lysis time method.
    Berg W; Korsan-Bengtsen K; Ygge J
    Thromb Diath Haemorrh; 1965 Sep; 14(1-2):127-44. PubMed ID: 16955971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
    Tanswell P; Tebbe U; Neuhaus KL; Gläsle-Schwarz L; Wojcik J; Seifried E
    J Am Coll Cardiol; 1992 Apr; 19(5):1071-5. PubMed ID: 1372625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peritoneal mesothelium--the role in fibrin transformations].
    Winckiewicz M; Staniszewski R; Połubińska A; Breborowicz A
    Przegl Lek; 2006; 63(9):778-81. PubMed ID: 17479869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Staphylokinase--a specific plasminogen activator].
    Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
    Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fucoidan, heparin and cyanogen bromide-fibrinogen on the activation of human glutamic-plasminogen by tissue plasminogen activator.
    Bell J; Duhon S; Doctor VM
    Blood Coagul Fibrinolysis; 2003 Apr; 14(3):229-34. PubMed ID: 12695744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stachybotrydial selectively enhances fibrin binding and activation of Glu-plasminogen.
    Sasaoka M; Wada Y; Hasumi K
    J Antibiot (Tokyo); 2007 Nov; 60(11):674-81. PubMed ID: 18057696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and plasma viscosity in experimentally induced hyper- and hypo-fibrinogenaemia.
    Pola P; Flore R; Tondi P
    Int J Tissue React; 1986; 8(4):333-6. PubMed ID: 2943690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
    Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
    Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of blood viscosity using a pressure-scanning capillary viscometer.
    Shin S; Ku Y; Park MS; Suh JS
    Clin Hemorheol Microcirc; 2004; 30(3-4):467-70. PubMed ID: 15258389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism.
    Mühl D; Füredi R; Gecse K; Ghosh S; Falusi B; Bogár L; Roth E; Lantos J
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):661-7. PubMed ID: 17890954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrochemical processing of fibrinogen modified-graphite surfaces: effect on plasmin generation from adsorbed plasminogen.
    Alfonsi-Hourdin S; Longchamp S; Gallet O; Nigretto JM
    Biomaterials; 2006 Jan; 27(1):52-60. PubMed ID: 16029886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
    Lobov S; Croucher DR; Saunders DN; Ranson M
    Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.